Oppenheimer Reiterates Outperform Rating on Kala Pharmaceuticals (KALA), PT $15
Tweet Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $15.00 price target on Kala Pharmaceuticals (NASDAQ: KALA).The analyst comments "KALA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
